资讯

GlobalData on MSN4 天
Eli Lilly strikes $1.3bn gene therapy deal with Rznomics
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
Eli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pact
Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...
Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy ...
Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...
Contract Pharma4 天
Rznomics & Eli Lilly Enter Global Licensing Agreement
Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...
Fierce Biotech4 天
Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact
Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...
BioSpace4 天
Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline
Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.
BioWorld5 天
Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug
Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss.